К ВОПРОСУ О ПРИМЕНЕНИИ ИНТЕРФЕРОНОВ I ТИПА ДЛЯ ЛЕЧЕНИЯ COVID-19

ПРЕПРИНТ

Эта статья является препринтом и не была отрецензирована.
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.

Мелехина Е. В.,

Николаева С. В.,

Усенко Д. В.,

Понежева Ж. Б.,

Музыка А. Д.,

Хлыповка Ю. Н.,

Шабалина С. В.,

Горелов А. В.

2020-09-12

https://doi.org/10.21055/preprints-3111812

Инфекция COVID-19 (CoronaVirus Disease — коронавирусная болезнь-2019), вызванная новым коронавирусом SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2 — тяжелый острый респираторный синдром), в настоящее время стала одной из самых значительных угроз общественному здоровью. Отличительной особенностью коронавирусов является их способность подавлять выработку ИФН I типа. Перспективным в раннем лечении и профилактике COVID-19 могут быть препараты ИФН I типа. На сегодняшний день поиск этиотропного препарата для лечения COVID-19 продолжается.

Ссылка для цитирования:

Мелехина Е. В., Николаева С. В., Усенко Д. В., Понежева Ж. Б., Музыка А. Д., Хлыповка Ю. Н., Шабалина С. В., Горелов А. В. 2020. К ВОПРОСУ О ПРИМЕНЕНИИ ИНТЕРФЕРОНОВ I ТИПА ДЛЯ ЛЕЧЕНИЯ COVID-19. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111812

Список литературы

1. Lim, Y.X., Ng, Y.L., Tam, J.P., and Liu, D.X. Human Coronaviruses: A Review of Virus-Host Interactions. Diseases 2016: 4, 26.

2. C. Qin, L. Zhou, Z. Hu, S. Zhang, S. Yang, Y. Tao, C. Xie, K. Ma, K. Shang, W. Wang, D.-S. Tian Dysregulation of immune response in patients with COVID-19 in Wuhan, China Clin. Infect. Dis. (2020), 10.1093/cid/ciaa248.

3. Lokugamage, K.G., Hage, A., Schindewolf, C., Rajsbaum, R., and Menachery, V.D. (2020). SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv, 2020.03.07.982264.

4. Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Nakagawa, S., and Sato, K. (2020). SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. bioRxiv, 2020.05.11.088179.

5. Chen, J., and Subbarao, K. The Immunobiology of SARS. Annu. Rev. Immunol. 2007: 25, 443–472.

6. Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T.X., Oishi, K., Panis, M., Sachs, D., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. 2020. Cell. S0092-8674(20)30489-X. https://doi.org/10.1016/j.cell.2020.04.026.

7. V.D. Menachery, B.L. Yount, L. Josset, L.E. Gralinski, T. Scobey, S. Agnihothram, M.G. Katze, R.S. Baric Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2’-O-Methyltransferase Activity J. Virol., 88 (2014), 4251-4264, 10.1128/jvi.03571-13.

8. T. Yoshikawa, T.E. Hill, N. Yoshikawa, V.L. Popov, C.L. Galindo, H.R. Garner, C.J. Peters, C. Te Tseng Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection PLoS One, 5 2010, 10.1371/journal.pone.0008729.

9. Channappanavar, R., Fehr, A.R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D.K., and Perlman, S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoVInfected Mice. Cell Host Microbe 2016: 19, 181–193.

10. Cameron, M.J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J.F., Cameron, C.M., Muller, M.P., Gold, W.L., Richardson, S.E., Poutanen, S.M., et al.; Canadian SARS Research Network. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 2007: 81, 8692–8706.

11. Eu Suk Kim, Pyoeng Gyun Choe, Wan Beom Park, Hong Sang Oh, Eun Jung Kim, Eun Young Nam, Sun Hee Na, Moonsuk Kim. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection J Korean Med Sci. 2016 Nov;31(11):1717-1725. English. https://doi.org/10.3346/jkms.2016.31.11.1717.

12. Wei, L., Ming, S., Zou, B., Wu, Y., Hong, Z., Li, Z., Zheng, X., Huang, M., Luo, L., Liang, J., et al. (2020). Viral Invasion and Type I Interferon Response Characterize the Immunophenotypes during COVID-19 Infection (SSRN Journal).

13. Stockman, L.J., Bellamy, R., and Garner, P. SARS: systematic review of treatment effects. PLoS Med. 2006: 3, e343.

14. Chan, J.F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. Treatment With Lopinavir/Ritonavir or Interferonb1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J. Infect. Dis. 2015: 212, 1904–1913.

15. Sheahan, T.P., Sims, A.C., Leist, S.R., Schafer, A., Won, J., Brown, A.J., Mont- € gomery, S.A., Hogg, A., Babusis, D., Clarke, M.O., et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020: 11, https://doi.org/10. 1038/s41467-019-13940-6.

16. Darryl Falzarano, Emmie de Wit, Angela L Rasmussen, Friederike Feldmann, Atsushi Okumura, Dana P Scott, Doug Brining, Trenton Bushmaker, Cynthia Martellaro, Laura Baseler, Arndt G Benecke, Michael G Katze, Vincent J Munster & Heinz Feldmann. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques Nature Medicine 2013: 19, 1313–1317.

17. Haagmans, B.L., Kuiken, T., Martina, B.E., Fouchier, R.A.M., Rimmelzwaan, G.F., van Amerongen, G., van Riel, D., de Jong, T., Itamura, S., Chan, K.-H., et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 2004: 10, 290–293.

18. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., Almakhlafi, G.A., Albarrak, M.M., Memish, Z.A., and Albarrak, A.M. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 2014: 14, 1090–1095.

19. Arabi, Y.M., Shalhoub, S., Omari, Al., et al. Effect of Ribavirin and Interferon on the Outcome of Critically Ill patients with MERS. Am. J. Respir. Crit. Care Med. 2017: 195, A6067.

20. Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., and Mushtaq, A. IFN-a2a or IFN-b1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J. Antimicrob. Chemother. 2015: 70, 2129–2132.

21. Lokugamage, K.G., Hage, A., Schindewolf, C., Rajsbaum, R., and Menachery, V.D. SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv, 2020.03.07.982264.

22. Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., and Huang, C.Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020: 179, 104811.

23. Sallard, E., Lescure, F.-X., Yazdanpanah, Y., Mentre, F., and Peiffer-Smadja, N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020: 178, 104791.

24. Zhou, Q., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Chen, V., Shannon, C.P., Tebbutt, S.J., Kollmann, T.R., and Fish, E.N. Interferon-a2b treatment for COVID-19. medRxiv, 2020.04.06.20042580.

25. Meng, Z., Wang, T., Li, C., Chen, X., Li, L., Qin, X., Li, H., and Luo, J. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv, 2020.04.11.20061473.

26. Jérôme Hadjadj, Nader Yatim, Laura Barnabei, Aurélien Corneau, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 10.1126/science.abc6027 (2020)

ПРЕПРИНТ

ИНФОРМАЦИЯ О ПРЕПРИНТЕ